CuraTeQ Biologics achieves milestone in Omalizumab biosimilar development
CuraTeQ Biologics Private Limited, a fully integrated arm of Aurobindo Pharma Ltd, has announced significant progress in its biosimilar program, revealing that its Omalizumab biosimilar ... Read More
Aurobindo Pharma achieves promising results for breast cancer biosimilar in Phase 3 trial
Aurobindo Pharma has announced positive results from a Phase 3 clinical trial of its breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed ... Read More